Valneva SE (NASDAQ:VALN - Get Free Report)'s stock price gapped down prior to trading on Tuesday . The stock had previously closed at $8.50, but opened at $8.15. Valneva shares last traded at $8.06, with a volume of 9,082 shares changing hands.
Wall Street Analyst Weigh In
Several research analysts have commented on the company. Guggenheim cut their price objective on Valneva from $18.00 to $17.00 and set a "buy" rating on the stock in a research report on Friday, March 22nd. HC Wainwright restated a "buy" rating and set a $26.00 target price on shares of Valneva in a research note on Thursday, March 21st.
Read Our Latest Analysis on VALN
Valneva Stock Down 5.9 %
The firm has a 50 day moving average price of $7.69 and a two-hundred day moving average price of $9.67. The company has a quick ratio of 1.37, a current ratio of 1.65 and a debt-to-equity ratio of 1.04. The company has a market capitalization of $555.67 million, a price-to-earnings ratio of -5.06 and a beta of 2.25.
Valneva (NASDAQ:VALN - Get Free Report) last announced its earnings results on Wednesday, March 20th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of $0.20 by ($0.70). The business had revenue of $45.12 million for the quarter, compared to analyst estimates of $45.06 million. Valneva had a negative net margin of 65.99% and a negative return on equity of 59.48%. As a group, sell-side analysts expect that Valneva SE will post 0.11 earnings per share for the current year.
Hedge Funds Weigh In On Valneva
A number of hedge funds have recently bought and sold shares of VALN. UBS Group AG acquired a new position in Valneva in the second quarter worth about $31,000. Jane Street Group LLC grew its stake in Valneva by 85.9% in the first quarter. Jane Street Group LLC now owns 16,584 shares of the company's stock worth $569,000 after purchasing an additional 7,664 shares in the last quarter. Finally, Bank of America Corp DE acquired a new position in Valneva in the first quarter worth about $858,000. 11.39% of the stock is currently owned by institutional investors and hedge funds.
Valneva Company Profile
(
Get Free Report)
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.
Further Reading
Before you consider Valneva, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Valneva wasn't on the list.
While Valneva currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
